NCT03118531View on ClinicalTrials.gov

China Resolute Integrity 34/38 mm Study

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

July 31, 2018

Study Completion Date

April 28, 2023

Conditions
Ischemic Heart DiseaseStenotic Coronary LesionCardiovascular DiseasesArteriosclerosisCoronary Artery Disease
Interventions
DEVICE

Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)

The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.

Trial Locations (2)

100000

Beijing Friendship Hospital, Beijing

350001

Fujian Medical University Union Hospital, Fuzhou

Sponsors

Lead Sponsor

Medtronic Vascular
All Listed Sponsors
lead

Medtronic Vascular

INDUSTRY

NCT03118531 - China Resolute Integrity 34/38 mm Study | Biotech Hunter | Biotech Hunter